Tumor Models Summit on July 29-30, 2026 in Boston, United States

Built by biopharma for biopharma, the 14th Tumor Models Summit Boston returns as the East Coast's leading meeting uniting oncology pharma, biotech, and model developers to close the translational gap with practical, next‑generation model strategies.

Join us this July 29-30 as we unite 210+ preclinical and translational leaders, and ensure you're equipped with the latest tumor modeling strategies to de-risk your own oncology pipelines before the move to the clinic.

This year expect brand new case studies on applying ex vivo, complex in vitro, humanized in vivo, and computational/AI enabled platforms to guide ADCs, T cell engagers, bispecifics, cell therapies, and degraders; Deeper focus on model selection under evolving regulatory expectations, including NAMs and FDA modernization updates; and more peer led, decision driven discussions on when a single model is sufficient versus when convergence across systems is required

Tickets are FREE* for biopharma!

URL:

Brochure: https://go.evvnt.com/3636164-2?pid=10008

Time: 8:00 AM - 4:00 PM

Price:

Free: USD 0.00

Speakers: Amanda Ouchida, Senior Scientist, Takeda, Bethany Mattson, Director - Innovative Medicine Oncology, Johnson and Johnson, Collin Walter, Senior Scientist, Regeneron, Daniela Dinulescu, Director, Tumor Immunobiology Clinical ICC Discovery Group, Oncology R and D, AstraZeneca, Isabel Jerchel-Furau, Associate Principal Scientist, Research Oncology, Bayer, Giulia Tamborino, Principal Scientist I, RLT Modeling and Simulation, Novartis, Katja Mohrs, Principal Scientist and Manager, Regeneron, Nasia Apostolou, Research Senior Scientist, Takeda, Rosa Ng, Associate Director, Oncology Biomedical Research, Novartis, Sowmya Balasubramanian, Senior Scientist, Translational Science, Astellas, Tamar Uziel, Scientific Director, Research Fellow, Oncology Translational Research, Lead Engineering and Technical, AbbVie, Zixiong Wang, Senior Scientist QB, Merck and Co., David Sherris, President and Chief Executive Officer, Attivare Therapeutics, Dmitry Malin, Senior Principal Scientist, K2B Therapeutics, Johanna Kaufmann, Chief Scientific Officer, Deck Bio, Howard Wu, Chief Scientific Officer, Full Circles Therapeutics, Jutta Deckert, Vice President, R and D Engineering and Technical, Iksuda Therapeutics, Lalit Kumar, Director, Clinical Bioanalytics and Translational Science, Beam Therapeutics, Shanmugarajan Krishnan, Principal Scientist, Agenus, Tony Arulanandam, Chief Executive Officer and Founder, Synaptimmune Therapeutics, Violet Young, Senior Research Associate, Mariana Oncology, Min Jae Song, Team Lead at 3D Tissue Bioprinting Laboratory, NCATS/NIH, Long Do, Chief Technology Officer AI/Bioinformatics, Certis Oncology, Michael Wick, Chief Scientific Officer, XenoSTART, Eric Ibsen, Chief Executive Officer and President, Studylog